Today: 11 June 2026
Datadog stock pops in premarket on Stifel upgrade as Feb. 10 earnings near
22 January 2026
1 min read

Datadog stock pops in premarket on Stifel upgrade as Feb. 10 earnings near

New York, Jan 22, 2026, 08:11 EST — Premarket

  • Datadog shares jumped roughly 3% in premarket action following a Stifel upgrade.
  • Quarterly results are due Feb. 10, followed by an Investor Day on Feb. 12.
  • Traders are focused on 2026 guidance and any hints of strength in cloud spending.

Datadog Inc shares climbed roughly 3% to $127.35 in early trading Thursday, building on a strong rally from Wednesday following Stifel’s upgrade of the software company. The stock closed Wednesday at $123.46, marking a 5.5% gain.

The upgrade comes as investors weigh if Datadog can speed up growth again in 2026 without relying heavily on a handful of major factors. Stifel’s recent channel checks suggest “another larger than typical” Q4 beat and described the stock’s valuation as “relatively attractive.” TipRanks

Datadog said earlier this week it will release its fourth-quarter and full-year 2025 results before U.S. markets open on Feb. 10, with a conference call scheduled for 8:00 a.m. Eastern.

Two days after that, the company will hold an Investor Day in New York City beginning at 1:00 p.m. Eastern on Feb. 12, per a separate announcement.

Stifel lowered its price target on Datadog to $160 from $205 but upgraded the stock to a “buy,” highlighting ongoing debates on Wall Street about how much investors should value software growth in 2026. The firm projects Datadog’s 2026 revenue to hit roughly $4.1 billion and called the implied core growth estimate “conservative.” TipRanks

Other firms have updated their models following the print. TD Cowen cut its price target to $200 from $235 but held onto a Buy rating, anticipating a “strong beat” against Datadog’s guidance, which points to about 24% growth. The firm also sees the 2026 revenue forecast of 19%-20% as probable. TipRanks

There’s still risk on the downside. Mizuho maintained its Outperform rating but lowered the price target to $170 from $200, citing concerns that worries over AI disruption are squeezing software valuations. The firm also noted that what’s usually a “budget flush” from year-end IT spending appeared more restrained than normal in some reports. TipRanks

Datadog offers a subscription platform designed for companies to monitor and troubleshoot their cloud applications and infrastructure. The industry refers to this as “observability,” a term that captures the ability to track system performance in real time and quickly pinpoint issues.

In the upcoming session, all eyes will be on DDOG to see if it can maintain its premarket gains when the Nasdaq bell rings. Investors will also be waiting to see if additional broker notes drop before the company reports earnings on Feb. 10. After that, the Feb. 12 Investor Day stands out as the next key event, with guidance and updates on customer spending expected to drive the stock’s moves.

Stock Market Today

  • Ford Stock Down 6% Over Five Years Amid Strategic Shift
    June 11, 2026, 10:58 AM EDT. Ford's stock has fallen 6% over five years, significantly underperforming the S&P 500's 71% gain despite a recent 20% rally. The company exited costly electric vehicle (EV) programs, launching Ford Energy to produce lithium-ion phosphate batteries for energy storage through a partnership with China's CATL. Investors remain cautious, focusing on Ford's reliance on domestic sales of its F-Series gas-powered trucks, its longstanding best-seller. Ford's strategic pivot away from EVs, admitting Chinese EV competition risks, and modest international presence contribute to lingering investor skepticism about its long-term value.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX
Previous Story

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Salesforce stock rebounds as Dow firms; Benioff’s Davos AI warning keeps CRM in focus
Next Story

Salesforce stock rebounds as Dow firms; Benioff’s Davos AI warning keeps CRM in focus

Go toTop